Loading company
Tango Therapeutics, Inc.
TNGX · Nasdaq · ·
Next earnings: November 3, 2026
$24.45+0.5%Sep 29 close
- 1M
- +9.4%
- 6M
- +15.2%
- 1Y
- +206.5%
- 5Y
- +84.4%
TNGX · Nasdaq · ·
Next earnings: November 3, 2026
$24.45+0.5%Sep 29 close
Tango Therapeutics, Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $3.2M | -100.00% |
| Profit | -$55.3M | -$38.9M | -42.44% |
| Profit per share | -$0.37 | -$0.35 | -5.71% |
| Free Cash Flow | -$38.8M | -$37.1M | -4.58% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter marked a pivotal period for Tango, with milestones that validated our PRMT5 inhibitor pipeline and reflect the progress of our maturing organization. Notably, initial Phase 1/2 data showed vopimetostat plus daraxonrasib achieved a 92% objective response rate with encouraging durability in MTAP-deleted, RAS-mutant pancreatic cancer, giving us the confidence to move this combination rapidly into Phase 3 development for patients,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Tango is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Tango Therapeutics, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Tango Therapeutics, Inc. has no earnings call transcript available.